{"prompt": "['3.1.2.3.', 'Safety Secondary Objectives:', 'The safety secondary objectives of this study are to determine the safety and tolerability', 'of lumateperone administered orally once daily for 6 weeks in patients with Bipolar', 'Depression, compared to placebo. Safety and tolerability will be assessed in relation to:', 'Incidence of adverse events (AEs);', 'Mean change from baseline in the Young Mania Rating Scale (YMRS);', 'Mean change from baseline in the Columbia Suicide Severity Rating Scale (C-', 'SSRS);', 'Mean change from baseline in the Abnormal Involuntary Movement Scale', '(AIMS);', 'Mean change from baseline in the Barnes Akathisia Rating Scale (BARS);', 'Mean change from baseline in the Simpson Angus Scale (SAS);', 'Changes from baseline in clinical laboratory evaluations;', 'Intra-Cellular Therapies, Inc. Confidential', '9 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['Changes from baseline in electrocardiograms (ECGs);', 'Changes from baseline in vital sign measurements;', 'Physical and neurological examination findings.', '3.2', 'Study Outcome Measures', '3.2.1 Primary', 'The change from baseline to Day 43 in MADRS total score is the primary outcome', 'measure for the study. The MADRS is defined in Section 8.2.1 and will be assessed', 'according to the Schedule of Events.', '3.2.2 Secondary', 'The key secondary outcome measure is change from baseline to Day 43 in CGI-BP-S', 'total score. CGI-BP-S is defined in section 8.1.9 and will be assessed according to the', 'Schedule of Events.', 'Other secondary efficacy outcome measures include change from baseline in the', 'MADRS, CGI-BP-S, and the Q-LES-Q-SF. These are described in Section 8 and will be', 'assessed according to the Schedule of Events.', 'The secondary safety outcome measures include AEs, YMRS, C-SSRS, AIMS, BARS,', 'SAS, clinical laboratory evaluations, ECGs, vital signs, and physical exams and', 'neurological findings. These are described in Section 8 and will be conducted', 'according to the Schedule of Events.', 'Intra-Cellular Therapies, Inc. Confidential', '10 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['4 STUDY DESIGN', 'This is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study to', 'evaluate the efficacy and safety of lumateperone monotherapy in the treatment of', 'patients with major depressive episodes associated with Bipolar I or Bipolar II Disorder', '(Bipolar Depression). The study consists of the following periods: Screening Period,', 'double-blind On-treatment Period, and Safety Follow-up Period.', 'Screening Period (2 Weeks)', 'Potential patients will be evaluated during a Screening Period lasting up to 2 weeks, to', 'ensure sufficient washout of restricted medications. Extension to the screening period', 'may be approved by the Sponsor or representative in extenuating circumstances', 'related to the patient or caregiver.', 'After obtaining written informed consent, diagnostic interviews and physical', 'examinations will be conducted, vital signs and ECGs will be assessed, and blood', 'samples for laboratory assessments will be collected. Patients considered potentially', 'eligible for participation will be required to discontinue their current antidepressant', 'treatment and/or other psychotropic drugs.', 'At baseline (Visit 2), patients who continue to meet all eligibility criteria will be randomly', 'assigned to 1 of the 2 treatment arms for a 6-week, double-blind treatment period.', 'Patients will be randomly assigned to 1 of the following groups: 60 mg ITI-007 or', 'matching placebo.', 'Double-Blind On-Treatment Period (6 Weeks)', 'Patients will take their first dose of study medication the evening of their baseline visit.', 'A single dose will be taken each day in the evening, with or without food, for the', 'duration of the 6-week On-treatment Period.', 'Following randomization, patients will attend the clinic on Days 8, 15, 22, 29, 36 and 43.', 'Safety Follow-up Period (2 Weeks)', 'A return to the clinic for a safety follow-up visit will occur at Week 8, approximately 2', 'weeks following the last dose of study medication. If possible, patients who withdraw', 'prematurely will be seen for an early termination visit (within 1 week of early', 'termination) and will be asked to return to the clinic for a safety follow-up visit 2 weeks', 'following withdrawal.', 'Intra-Cellular Therapies, Inc. Confidential', '11 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}